191 related articles for article (PubMed ID: 18175773)
1. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
3. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
[TBL] [Abstract][Full Text] [Related]
4. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P
Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072
[TBL] [Abstract][Full Text] [Related]
5. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
[TBL] [Abstract][Full Text] [Related]
6. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
[TBL] [Abstract][Full Text] [Related]
7. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
9. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
Arca M; Gaspardone A
Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
[TBL] [Abstract][Full Text] [Related]
12. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
Sever PS; Poulter NR; Dahlöf B; Wedel H;
Am J Cardiol; 2005 Sep; 96(5A):39F-44F. PubMed ID: 16126022
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
14. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Manisty C; Mayet J; Tapp RJ; Sever PS; Poulter N; McG Thom SA; Hughes AD;
Hypertension; 2009 Nov; 54(5):1009-13. PubMed ID: 19720956
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Sever PS; Poulter NR; Chang CL; Hingorani A; Thom SA; Hughes AD; Welsh P; Sattar N;
Eur Heart J; 2012 Feb; 33(4):486-94. PubMed ID: 21798891
[TBL] [Abstract][Full Text] [Related]
19. Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Brown WV; Moussa M
Curr Opin Lipidol; 2003 Dec; 14(6):593-7. PubMed ID: 14624136
[TBL] [Abstract][Full Text] [Related]
20. Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Chapman N; Chang CL; Caulfield M; Dahlöf B; Feder G; Sever PS; Poulter NR
Ethn Dis; 2011; 21(2):150-7. PubMed ID: 21749017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
